XCancer

Mechanisms of Resistance to PSMA Radioligand Therapy

Description:

This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.

Sponsor:

University of California, San Francisco

Contacts:

Thomas Hope, MD (PRINCIPAL_INVESTIGATOR)

Maya Aslam (CONTACT)

maya.aslam@ucsf.edu

(415) 514-8987

Government Study Link:

NCT05435495 - Click here to see study on

ClinicalTrials.gov

PSMA-RLT

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: DOTA
Inclusion
  • Initiating treatment with Lutetium based PSMA-targeted RLT.
  • Participants must have a PSMA-avid lesion that is accessible to biopsy. Biopsy of newly emerging radiographic metastases is desired and preferable to the biopsy of previously existing lesions whenever possible. Newly emerging lesions are defined as those that are absent on a previous scan, or those demonstrating unequivocal progression since initiation of the last treatment. Biopsies will be performed according to local institutional standards.
Exclusion
  • Patients with significant congenital or acquired bleeding disorders (eg von Wildebrand's disease, acquired bleeding factor inhibitors).